TITLE

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial

AUTHOR(S)
Gallant, Joel E.; Staszewski, Schlomo; Pozniak, Anton L.; DeJesus, Edwin; Suleiman, Jamal M. A. H.; Miller, Michael D.; Coakley, Dion F.; Lu, Biao; Toole, John J.; Cheng, Andrew K.
PUB. DATE
July 2004
SOURCE
JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p191
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n = 299) or stavudine (n = 303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exceeding the predefined -10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA <50 copies/mL) at week 48 and through 144 weeks. Virologic failure was associated most frequently with efavirenz and lamivudine resistance. Through 144 weeks, the K65R mutation emerged in 8 and 2 patients in the tenofovir DF and stavudine groups, respectively (P = .06). A more favorable mean change from baseline in fasting lipid profile was noted in the tenofovir DF group at week 144: for triglyceride levels (+1 mg/dL for tenofovir DF [n = 170] vs +134 mg/dL for stavudine [n = 162], P<.001), total cholesterol (+30 mg/dL [n = 170] vs +58 mg/dL [n = 162], P<.001), direct low-density lipoprotein cholesterol (+14 mg/dL [n = 169] vs +26 mg/dL [n ...
ACCESSION #
13833491

 

Related Articles

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • Treatment of HIV/AIDS: Do the Dilemmas Only Increase? Sande, Merle A.; Ronald, Allan // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p266 

    Presents an editorial on HIV/AIDS treatment and mentions articles in this issue of "JAMA". Guidelines set by the International AIDS Society-USA (IAS-USA) for HIV care reported in this issue; View that clinical trials using highly active antiretroviral therapy (HAART) should be redirected to...

  • Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel. Yeni, Patrick G.; Hammer, Scott M.; Hirsch, Martin S.; Saag, Michael S.; Schechter, Mauro; Carpenter, Charles C. J.; Fischl, Margaret A.; Gatell, Jose M.; Gazzard, Brian G.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S. G.; Richman, Douglas D.; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Volberding, Paul A. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p251 

    Context Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. Objective To update recommendations for physicians who provide...

  • Clinical Trials in Sub-Saharan Africa and Established Standards of Care: A Systematic Review of HIV, Tuberculosis, and Malaria Trials. Kent, David M.; Mwamburi, D. Mkaya; Bennish, Michael L.; Kupelnick, Bruce; Ioannidis, John P. A. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p237 

    Context The minimum standard of care required for participants in clinical trials conducted in resource-poor settings is a matter of controversy; international documents offer contradictory guidance. Objective To determine whether recently published trials conducted in sub-Saharan Africa met...

  • Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). Torti, Carlo; Raffetti, Elena; Donato, Francesco; Castelli, Francesco; Maggiolo, Franco; Angarano, Gioacchino; Mazzotta, Francesco; Gori, Andrea; Sighinolfi, Laura; Pan, Angelo; Cauda, Roberto; Scalzini, Alfredo; Quiros-Roldan, Eugenia; Nasta, Paola; Gregis, Giampietro; Benatti, Simone; Digiambenedetto, Simona; Ladisa, Nicoletta; Giralda, Mariarosaria; Saracino, Annalisa // International Journal of Epidemiology;Apr2017, Vol. 46 Issue 2, p1 

    No abstract available.

  • DisfuncÈ›ia endotelială, lipodistrofia ÅŸi sindromul metabolic la pacienÈ›i infectaÈ›i cu HIV. PAPIȚĂ, ANAMARIA; ALBU, ADRIANA; ITU, CORINA; CÂRSTINA, D. // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p185 

    HIV infection has become in our days a chronic disease due to the efficiency of antiretroviral (ARV) treatment. Soon after the introduction of this treatment its complications related to metabolic disturbances have been observed and studied. Metabolic syndrome was particularly described in...

  • Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L. // AIDS & Behavior;May2006, Vol. 10 Issue 3, p273 

    Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample...

  • Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. Bonjoch, Anna; Pou, Christian; Pérez-Álvarez, Núria; Bellido, Rocío; Casadellà, Maria; Puig, Jordi; Noguera-Julian, Marc; Clotet, Bonaventura; Negredo, Eugènia; Paredes, Roger // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1382 

    Objectives To evaluate the safety and efficacy of switching the third drug of antiretroviral treatment to maraviroc in aviraemic subjects infected with R5 HIV. Patients and methods This is a pilot, prospective, randomized clinical trial (ClinicalTrials ID: NCT00966329). Eighty HIV-1-infected...

  • Antiretrovirals.  // Reactions Weekly;1/22/2011, Issue 1335, p8 

    The article describes the case of three patients who acquired HIV-associated lipodystrophy while undergoing antiretroviral therapy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics